Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression
JAMA Network Open July 30, 2025 Fredrik Hieronymus, Evana López, Helena Werin Sjögren et al. 21 citations
Importance Psilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for conventional antidepressants. However, concerns have been raised that high rates of functional unblinding in combination with trial participants with positive expectations of psychedelic use might bias treatment outcomes. Objective To compare...